

14th Australian Influenza Symposium

Thursday 11 November 2021

Doherty Institute, Melbourne

Program Day 1

0800	Registration desk opens	
0900	Meeting opening and logistics: Ian Barr, WHO CC, Doherty Institute, Melbourne, VIC	
0910	Opening remarks	
Plenary Session 1: COVID-1 Basics Chair: Kanta Subbarao, WHO CC, Doherty Institute, Melbourne, VIC		
0915	Eddie Holmes; Marie Bashir Institute for Infectious Diseases & Biosecurity, University of Sydney	The Origins of SARS-CoV-2
0945	Stanley Perlman; Department of Microbiology and Immunology, University of Iowa Distinguished Chair, USA	Human coronaviruses; lessons from SARS-CoV, MERS and now SARS-CoV-2
1015	Jenifer Juno; Department of Microbiology and Immunology, University of Melbourne, Doherty Institute	Host immune responses to SARS-CoV-2
1045	<i>Morning tea</i>	
Plenary Session 2: COVID-2 Epidemiology, Vaccines and Antivirals Chair: TBC		
1115	Freya Sheare; Department of Microbiology and Immunology, University of Melbourne	Epidemiology and impact of SARS-CoV-2 in Australia
1135	Sarah Cobey; Department of Ecology and Evolution, University of Chicago, USA	Epidemiological insights into the global COVID-19 pandemic
1155	Kanta Subbarao; WHO CC for Influenza, VIDRL, Doherty Institute	Vaccine and antivirals to SARS-CoV-2
1215	Peter McIntyre; Department of Women's and Children's Health, University of Otago, Dunedin, NZ	SARS-CoV-2 Vaccine roll outs – the good the bad and the ugly
1235	Jemma Geoghegan; Department of Microbiology and Immunology, Otago University, NZ	Tracking COVID-19 in New Zealand using genomics
100	<i>Lunch</i>	
Plenary Session 3: Influenza – Chair: TBC		
1345	Sheena Sullivan; WHO CC for Influenza, VIDRL, Doherty Institute	The 2020/2021 influenza seasons in Australia and what to expect in 2022
1405	Stella Liong; School of Health and Biomedical Sciences, STEM College, RMIT University	Influenza infection during pregnancy causes maternal vascular dysfunction and fetal growth restriction in mice
1425	Craig Dalton; School of Medicine and Public Health, Newcastle University	Influenza & COVID-19 electronic surveillance in 2020-2021
1445	Michelle Wille; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney	Evolutionary ecology of avian influenza A virus in Australia
Roundtable Discussion Chair: TBC		
1505	For discussion: Measures to mitigate airborne virus transmission Panel Members: TBC	
1530	<i>Afternoon tea</i>	
Workshop 1: Research Chair: TBC		
1600		
1615		
1630	SPEAKERS BASED ON SUBMITTED ABSTRACTS	
1645		
1700		
1715		
1730		
1745	Day 1 concludes: Drinks and finger food in foyer	

14th Australian Influenza Symposium

Friday 12 November 2021

Doherty Institute, Melbourne

Program Day 2

Plenary Session 4: Industry – Commercial and product updates | Chair: TBC

0830	Deb Williamson; Royal Melbourne Hospital, University of Melbourne, VIDRL, Doherty Institute	Diagnostics for SARS-CoV-2 antigen detection
0850	Suellen Nicolson; VIDRL, Doherty Institute	Diagnostics for SARS-CoV-2 antibody detection
0910	Bev Menner; COVID Vaccine Lead, CSL Limited	Making the AZ SARS-CoV-2 vaccine in Melbourne
0930	Nik Petrovsky; Department of Diabetes and Endocrinology, Flinders Medical Centre	Australia's Covax-19 vaccine: locally developed, overseas bound
0950	Raburn Mallory, Vice President Clinical Development Novavax, Gaithersburg, MD, USA	Safety and Immunogenicity of a Booster dose of the Novavax vaccine
1010	Keith Chappell; School of Chemistry and Molecular Biosciences, University of Queensland	UQ vaccine developments
1030	<i>Morning tea</i>	

Workshop 2: Epidemiology | Chair: TBC

1100		
1115		
1130	SPEAKERS BASED ON SUBMITTED ABSTRACTS	
1145		
1200		
1215		
12:30	<i>Lunch</i>	

Plenary Session 5: | Chair: TBC

1315	Bette Liu; School of Public Health and Community Medicine, UNSW	Influenza vaccine coverage in CALD adults and what we can learn for COVID vaccine coverage?
1340	Robert Booy; Child & Adolescent Health, The Children's Hospital at Westmead, Sydney University	Annual winter vaccination programs in the future – how do we incorporate; SARS-CoV-2 boosters, influenza/pneumonia/other vaccines
1405	Kristine Macartney; National Centre for Immunisation Research and Surveillance (NCIRS), Sydney	The AIR 2021; What have we learnt for COVID-19, influenza, and other vaccinations – update on its performance/acceptance
1430	Colin Pouton; Pharmacy & Pharmaceutical Sciences, Monash University (Parkville)	SARS-CoV-2 and the future of mRNA vaccines
1500	<i>Afternoon tea</i>	

RSV session | Chair: TBC

1530	John-Sebastian Eden; Centre for Virus Research, Westmead Institute for Medical Research, Sydney	RSV outbreaks in Australia in 2020-2021
1555	Gemma Saravanos; Children's Hospital at Westmead, The University of Sydney	The clinical epidemiology of RSV in children: subtypes, severity & syndromes
1620	Ian Barr; WHO CC for Influenza, VIDRL, Doherty Institute	WHO RSV global surveillance program – Phase 2 – An update
1645	Patricia Campbell; Department of Infectious Diseases, University of Melbourne, Doherty Institute	Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting
1715	Australian Influenza Symposium concludes	